From June 28, 2022 post.
Sens. Chuck Grassley (R-Iowa), Joe Manchin (D-W.Va.), Joni Ernst (R-Iowa) and John Kennedy (R-La.) are pressing the Federal Trade Commission (FTC) and the Horseracing Integrity and Safety Authority (the Authority) for answers on its implementation and enforcement of certain guidelines under the Horseracing Integrity and Safety Act (HISA). Specifically, the senators draw attention to the Anti-Doping and Medication Control program, which HISA requires to be implemented by July 1, 2022. However, the Authority has already stated it would not meet that deadline.
“HISA required the Authority to issue the rule for Anti-Doping and Medication Control not later than 120 days before the program effective date of July 1, 2022. This deadline has passed, and it appears the Authority failed to meet the statutory requirements. The FTC requires the Authority to submit any proposed rule at least 90 days before the proposed rule is to be published in the Federal Register for public comment. We are also not aware of any request or approval of a waiver of this requirement,” the lawmakers wrote.
Additionally, the senators raise concerns about new rules regarding horseshoes and riding crop specifications – initially set to take effect on July 1 under the Racetrack Safety Program – that were impossible for industry stakeholders to implement due to supply chain issues.
“This chaotic implementation process and poor communication by the Authority makes it difficult for industry participants to comply with the new rules and regulations. Additionally, continuously changing implementation dates for new rules and regulations, and last minute delays, cause more confusion and difficulty with implementation,” the lawmakers continued.
Grassley, Manchin, Ernst and Kennedy further argue that the Authority’s haphazard approach to setting fee structures will leave racetracks “without the certainty and transparency they need to budget for the current and future racing seasons.”
In conclusion, the senators ask the FTC and the Authority to explain why the July 1 deadline to implement the Anti-Doping and Medication Control Program will not be met, answer for their failure to issue a rule prior to the date required by HISA and clarify whether experts and stakeholders were consulted in the initial drafting of these rules.
Original source can be found here
